Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study."

Haematologica. 2021 Apr 1;106(4):1226-1227. doi: 10.3324/haematol.2020.278203.

Authors

Marco Picardi¹, Claudia Giordano²

Affiliations

¹ Department of Clinical Medicine and Surgery, Hematology Unit, Federico II University Medical School, Naples.
² Department of Clinical Medicine and Surgery, Hematology Unit, Federico II University Medical School, Naples. [email protected].

No abstract available

Publication types

Comment

MeSH terms

Brentuximab Vedotin
Cisplatin
Cytarabine
Dexamethasone
Hodgkin Disease* / drug therapy
Humans
Immunoconjugates*
Neoplasm Recurrence, Local
Salvage Therapy

Substances

Immunoconjugates
Cytarabine
Dexamethasone
Brentuximab Vedotin
Cisplatin